Nuclear Stock Face-Off: Is NuScale or BWX Technologies the Better Buy Right Now?

BWX Technologies is presented as the stronger nuclear stock, with its shares up nearly 90% over the past 12 months versus NuScale's more than 50% decline. BWX's year-end backlog grew 50% year over year to $7.3 billion in 2025, and analysts expect 13% revenue CAGR and 17% EPS CAGR from 2025 to 2028. NuScale remains highly speculative, with first commercial reactors not expected until 2030 at the earliest and continued losses through the forecast period.

Analysis

The market is effectively separating “nuclear exposure” into two very different duration trades: BWXT is becoming the picks-and-shovels beneficiary of defense-driven procurement, while SMR remains a financing-and-timing bet on a future industrial rollout. That matters because the AI/data-center narrative is mostly a demand argument, but the monetization path for SMR still depends on regulatory approvals, utility capital budgets, and project execution over a 3-5 year window. In a higher-rate regime, the present value penalty on that back-end cash flow is severe, which helps explain why the market is rewarding near-term backlog conversion over long-dated optionality.

Second-order winners tilt toward the nuclear supply chain rather than reactor developers. If BWXT continues to win regulated fuel, component, and naval work, that can pressure smaller SMR developers to either license, partner, or accept unfavorable economics as the ecosystem consolidates around the few firms with actual manufacturing, handling, and compliance capability. FLR’s exit is a signal that strategic holders may not want to fund the long gestation period; that raises the cost of capital for the whole SMR cohort and could force equity dilution or slower deployment timelines.

The main contrarian risk is that BWXT’s premium may already be pricing in a smooth conversion of backlog into earnings. If defense appropriations flatten or submarine timing slips, the multiple could compress even with solid fundamentals. Conversely, SMR’s drawdown may be overdone if one or two catalysts land: a credible financing package, a faster-than-expected licensing milestone, or a utility/sovereign customer using nuclear as a load-growth hedge against AI power demand.

This is a classic “quality duration” versus “speculative convexity” setup. For now, the market is paying up for cash-flow visibility and regulatory scarcity, not for theoretical TAM, and that should persist until capital becomes cheaper or SMR proves repeatable deployment economics.

Key Decisions for Investors

• Long BWXT into the next 1-3 quarters on pullbacks; favor the name as a lower-beta nuclear proxy with visible backlog-to-revenue conversion and defense insulation. Use a 10-15% trailing stop because the main risk is valuation compression, not thesis failure.
• Pair trade: long BWXT / short SMR for 3-6 months. This isolates execution quality versus speculative optionality; the trade works if rates stay elevated and SMR keeps slipping on financing or permitting.
• Avoid chasing SMR common until a concrete project-financing or licensing catalyst emerges; if taking exposure, prefer call spreads 12-24 months out to cap downside from timeline slippage.
• Watch FLR and other strategic holders/partners for any further exits or contract restructuring; those would be a negative signal for the SMR ecosystem and could create a tactical short opportunity on any relief rally.
• If BWXT approaches a higher-multiple breakout without backlog re-acceleration, consider selling upside via covered calls over 1-2 quarters to monetize premium while limiting exposure to multiple compression.